The University of Washington’s (UW) technology transfer division, CoMotion, has aided in the formation of seven new startups from UW-related research since last July. These companies, which range across sectors such as medicine and advanced technology, demonstrate the innovation and entrepreneurial drive nurtured at UW.
Several of these startups are making significant strides, such as Apetur and Polyfos. Apetur is dedicated to harnessing the functionality of smartphones to measure pupil size, identifying potential neurological conditions. Meanwhile, Polyfos is set to reshape manufacturing through improved 3D printing techniques. Other startups like Blynk, Nanotech, GreenEnergy, and ClickInk are capitalizing on opportunities in their respective fields to bring about significant change.
CoMotion, initially established in 1983, has been instrumental in the commercialization of UW research. Over the previous five years, UW has created 52 startups, issued over 2,000 licenses, and now houses 110 active spinouts. These offshoot companies employ more than 1,000 individuals, underscoring the far-reaching impact of CoMotion’s initiatives.
Among the seven new spinoffs, each is addressing a unique set of challenges. Axiss Bio is working on a distinctive molecule-based cancer treatment, while Histone Therapeutics is exploring precision epigenetic reprogramming. OxiGenetix is developing innovative oxygen delivery systems, femaLOGIC is pioneering personalized women’s healthcare solutions, and Nathan BioSolutions is working on holistic approaches to stroke recovery and cardiovascular health improvements. Additionally, SciPhi Therapeutics and PathoFree are redefining treatment and preventive strategies for neurological disorders and hospital-acquired infections, respectively.
More startups such as Kinea Bio are fast-tracking the development of gene therapies for neuromuscular conditions. SunDash Therapeutics is focusing on Duchenne muscular dystrophy treatments, and ReModify is creating high-definition DNA arrays for research. GeneFix Biotech has made monumental progress in novel genetic engineering techniques for the treatment of rare genetic disorders. MiraGenix is also intent on developing genome editing tools for numerous scientific and medical applications.
These startups not only indicate the global influence of UW in technology transfer and development but also articulate the university’s commitment to fostering a culture of innovation, entrepreneurship, and collaboration between academia and industry. This directive aligns seamlessly with UW’s overarching mission, namely, to lay the groundwork for breakthrough innovations that lead to economic expansion on regional and global scales.
